Telisotuzumab Vedotin联合厄洛替尼治疗c-Met蛋白表达非小细胞肺癌的Ib期研究
该Ib期研究评估Teliso-V(2.7 mg/kg每21天一次)联合厄洛替尼(150 mg每日一次)在c-Met阳性非小细胞肺癌患者中的安全性、药代动力学、客观缓解率和无进展生存期。截至2020年1月,42例入组,36例可评估疗效;神经病变为最常见不良事件(24/42,57%)。EGFR突变阳性患者(n=28)客观缓解率为32.1%,其中c-Met高表达者(n=15)为52.6%。
要点
- Teliso-V联合厄洛替尼在EGFR TKI经治的EGFR突变阳性、c-Met阳性NSCLC中显示鼓舞人心的抗肿瘤活性和可接受的毒性。
- 可评估疗效患者中位无进展生存期为5.9个月(95%CI,2.8至未达到)。
- EGFR突变阳性患者客观缓解率为32.1%,c-Met高表达者客观缓解率为52.6%。
核心结论
- Teliso-V联合厄洛替尼在EGFR TKI经治的EGFR突变阳性、c-Met阳性非小细胞肺癌患者中显示出鼓舞人心的抗肿瘤活性和可接受的毒性。
研究设计与样本
- Ib期研究(ClinicalTrials.gov标识符:NCT02099058),评估Teliso-V(2.7 mg/kg每21天一次)联合厄洛替尼(150 mg每日一次)在成人(年龄≥18岁)c-Met阳性非小细胞肺癌患者中的安全性、药代动力学、客观缓解率和无进展生存期。
- 后期入组要求存在EGFR激活突变(EGFR-M+)且既往EGFR TKI治疗进展。
- 疗效可评估人群为经确认组织学H评分≥150且至少有一次基线后扫描的c-Met阳性患者;H评分≥225的c-Met阳性患者归类为c-Met高表达。
- 截至2020年1月,共入组42例患者,其中36例可评估疗效。
主要发现
- 神经病变是最常见的任何级别不良事件,42例患者中24例(57%)经历至少一次事件。
- Teliso-V联合厄洛替尼的药代动力学特征与Teliso-V单药治疗相似。
- 所有可评估疗效患者的中位无进展生存期为5.9个月(95%CI,2.8至未达到)。
- EGFR突变阳性患者(n=28)的客观缓解率为32.1%。
- EGFR突变阳性患者中,c-Met高表达者(n=15)的客观缓解率为52.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Overexpression of c-Met protein and epidermal growth factor receptor (EGFR) mutations can co-occur in non-small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable safety profile and antitumor activity as monotherapy. Herein, we report the results of a phase Ib study (ClinicalTrials.gov identifier: NCT02099058) evaluating Teliso-V plus erlotinib, an EGFR tyrosine kinase inhibitor (TKI), in patients with c-Met-positive (+) NSCLC. PATIENTS AND METHODS: This study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 years) with c-Met+ NSCLC. Later enrollment required presence of an EGFR-activating mutation (EGFR-M+) and progression on a prior EGFR TKI. End points included safety, pharmacokinetics, objective response rate (ORR), and progression-free survival (PFS). The efficacy-evaluable population consisted of c-Met+ patients (confirmed histology [H]-score ≥ 150) who had at least one postbaseline scan; c-Met+ patients with H-scores ≥ 225 were classified as c-Met high. RESULTS: As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached). ORR for EGFR-M+ patients (n = 28) was 32.1%. Of EGFR-M+ patients, those who were c-Met high (n = 15) had an ORR of 52.6%. Median PFS was 6.8 months for non-T790M+ and for those whose T790M status was unknown, versus 3.7 months for T790M+. CONCLUSION: Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with EGFR-M+, c-Met+ NSCLC.
引用
- Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2022. PMID: 36288547. doi:10.1200/JCO.22.00739
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。